Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Iradimed (IRMD) has disclosed EPS (Weighted Average and Diluted) for 13 consecutive years, with $0.43 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 7.5% to $0.43 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.65, a 13.01% increase, with the full-year FY2024 number at $1.5, up 11.11% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.43 for Q3 2025 at Iradimed, down from $0.45 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.45 in Q2 2025 to a low of $0.11 in Q1 2021.
  • A 5-year average of $0.31 and a median of $0.32 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 520.0% in 2021; the steepest drop was 21.43% in 2021.
  • Iradimed's EPS (Weighted Average and Diluted) stood at $0.31 in 2021, then dropped by 3.23% to $0.3 in 2022, then rose by 20.0% to $0.36 in 2023, then rose by 11.11% to $0.4 in 2024, then increased by 7.5% to $0.43 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's EPS (Weighted Average and Diluted) are $0.43 (Q3 2025), $0.45 (Q2 2025), and $0.37 (Q1 2025).